uniQure N.V. Ordinary Shares
QURE NL0010696654
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -44% | 5% | -69% | 155% | 0% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Klemt Christian CFO |
55.00 USD |
15,000 Sold |
825,000 USD |
24/09/2025 | 26/09/2025 |
| Klemt Christian CFO |
40.04 USD |
3,000 Sold |
120,120 USD |
24/09/2025 | 24/09/2025 |
| Kapusta Matthew C CEO |
41.69 USD |
5,022 Sold |
209,367 USD |
24/09/2025 | 24/09/2025 |
| Kapusta Matthew C CEO |
39.59 USD |
51,316 Sold |
2,031,600 USD |
24/09/2025 | 24/09/2025 |
| Kapusta Matthew C CEO |
40.04 USD |
60,000 Sold |
2,402,400 USD |
24/09/2025 | 24/09/2025 |
| Kapusta Matthew C CEO |
40.68 USD |
49,978 Sold |
2,033,105 USD |
24/09/2025 | 24/09/2025 |
| Kapusta Matthew C CEO |
45.10 USD |
60,000 Sold |
2,706,000 USD |
24/09/2025 | 24/09/2025 |
| Abi-saab Walid CMO |
13.92 USD |
1,466 Sold |
20,407 USD |
27/06/2025 | 27/06/2025 |
| Kaye Jack O |
14.45 USD |
2,112 Sold |
30,518 USD |
20/06/2025 | 20/06/2025 |
| Gut Robert O |
14.45 USD |
3,336 Sold |
48,205 USD |
20/06/2025 | 20/06/2025 |